Filip Dubovsky - 17 Jun 2024 Form 4 Insider Report for NOVAVAX INC (NVAX)

Reporting relationship: President, R&D
Issuer ticker: NVAX
Reported as of: 17 Jun 2024
Net transaction value: -$201,164
SEC form: 4
Accepted by SEC: 20 Jun 2024, 17:08:39 UTC
Prior SEC filing: 15 May 2024
Source filing: View source filing
Reporting owner signature: /s/Mark J. Casey, Attorney-in-Fact

Key filing fact

Filip Dubovsky filed Form 4 for NOVAVAX INC (NVAX) on 20 Jun 2024.

Key facts

This page summarizes Filip Dubovsky's Form 4 filing for NOVAVAX INC (NVAX).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 20 Jun 2024, 17:08.

Change

Previous filing in this sequence was filed on 15 May 2024.
Current net transaction value: -$201,164.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NVAX transaction

Common Stock

Options Exercise

Transaction value: $9,786
Shares: +1,404
Change %: +2.1%
Price: $6.97
Shares after: 68,017
Date: 17 Jun 2024
Ownership: Direct

NVAX transaction

Common Stock

Options Exercise

Transaction value: $76,125
Shares: +12,500
Change %: +18%
Price: $6.09
Shares after: 80,517
Date: 17 Jun 2024
Ownership: Direct

NVAX transaction

Common Stock

Sale

Transaction value: $180,750
Shares: -12,500
Change %: -16%
Price: $14.46
Shares after: 68,017
Date: 17 Jun 2024
Ownership: Direct

NVAX transaction

Common Stock

Sale

Transaction value: $20,414
Shares: -1,404
Change %: -2.1%
Price: $14.54
Shares after: 66,613
Date: 17 Jun 2024
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NVAX transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $9,786
Shares: -1,404
Change %: -2.9%
Price: $6.97
Shares after: 46,324
Date: 17 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,404
Exercise price: $6.97
Footnotes: F1

NVAX transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $76,125
Shares: -12,500
Change %: -25%
Price: $6.09
Shares after: 37,500
Date: 17 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,500
Exercise price: $6.09
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.